[Ip-health] Open letter to Gilead: Global civil society calls for no patents or exclusivities on potential COVID-19 treatment

Shailly GUPTA Shailly.GUPTA at geneva.msf.org
Fri Apr 3 03:14:32 PDT 2020

Hi All

More than 150 organizations and individuals from global health movement sent an open letter<https://msfaccess.org/open-letter-civil-society-urges-gilead-take-immediate-action-ensure-access-potential-covid-19> this week to Gilead’s CEO sharing concerns about Gilead’s current approach to remdesivir, which may obscure access to this potentially critical treatment for COVID-19.

Gilead holds primary patents of remdesivir in more than 70 countries that may block generic entry until 2031. In the letter, Gilead was urged to take immediate actions to:

- Declare that Gilead will not enforce and claim exclusive rights on patents and regulatory and trial data, or any other types of exclusivity anywhere in the world;

- Make publicly available all data, sample products, and know-how that are needed for generic development and for regulatory processes, to facilitate the production and supply by generic manufacturers worldwide; and

- Improve transparency by disclosing its manufacturing capacity and existing supply and allow independent and proper governance over the allocation of the treatment according to medical needs.



Shailly Gupta
MSF Access Campaign
Geneva, Switzerland
+41- 79 203 13 02

More information about the Ip-health mailing list